Most public controversies about the effects of chemicals on human health revolve around the risk of cancer—hardly surprising, considering that it is the second leading cause of death in the United States. People are concerned about the dangers of carcinogens in air, water, and food, and they expect their representatives in government to protect them from such hazards. On the other hand, the economic costs of eliminating every suspected carcinogen from the environment would cause tremendous economic hardship. How should policymakers use science to help strike a balance between the benefits of lowering the risk of cancer and the economic costs of regulation?

In this important book the authors squarely address the complex interaction of science and regulatory policy. They begin by clarifying the scientific issues that are central to regulatory decisions, then explain how and why scientists can honestly disagree about these issues. They demonstrate with two cogent case studies: the heated debates about formaldehyde and benzene, both useful but potentially toxic chemicals. By examining how scientists evaluated the risks from these chemicals, and what kinds of legislative, administrative, and judicial decisions emerged from the evaluations, the authors furnish insight into the checks and balances of health-risk regulation.

They point out that overselling science in this context is harmful to both science and democracy. Their final chapter proposes creative methods for constructing a bridge between the scientist and the regulator that will be invaluable to anyone concerned about health risks.

Global health problems require global solutions, and public–private partnerships are increasingly called upon to provide these solutions. Such partnerships involve private corporations in collaboration with governments, international agencies, and nongovernmental organizations. They can be very productive, but they also bring their own problems. This volume examines the organizational and ethical challenges of partnerships and suggests ways to address them. How do organizations with different values, interests, and world-views come together to resolve critical public health issues? How are shared objectives and shared values created within a partnership? How are relationships of trust fostered and sustained in the face of the inevitable conflicts, uncertainties, and risks of partnership?

This book focuses on public–private partnerships that seek to expand the use of specific products to improve health conditions in poor countries. The volume includes case studies of partnerships involving specific diseases such as trachoma and river blindness, international organizations such as the World Health Organization, multinational pharmaceutical companies, and products such as medicines and vaccines. Individual chapters draw lessons from successful partnerships as well as troubled ones in order to help guide efforts to reduce global health disparities.